Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 3/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14033522 | 0.83 | GPR88 (0.51) | GPR88PARP15PARP10PARP2FNTA | |
| SCHEMBL4525746 | 0.82 | PARP15 (0.54) | GPR88PARP15PARP10PARP2FFAR1 | |
| SCHEMBL8422265 | 0.81 | ACACB (0.44) | GPR88LTA4HPARP15PARP10PARP2 | |
| SCHEMBL1990800 | 0.80 | TDP1 (0.57) | PARP15PARP10PARP2 | |
| SCHEMBL30932889 | 0.79 | PARP15 (0.51) | GPR88PARP15PARP10PARP2FFAR1 | |
| SCHEMBL28408055 | 0.79 | GPR88 (0.60) | GPR88PARP15PARP10PARP2FNTA | |
| SCHEMBL20490289 | 0.78 | GPR88 (0.59) | GPR88PARP15PARP10PARP2FNTA | |
| SCHEMBL14033970 | 0.78 | PDE4B (0.41) | FFAR1 | |
| SCHEMBL29024848 | 0.78 | PARP15 (0.64) | PARP15PARP10PARP2 | |
| SCHEMBL11247511 | 0.77 | LTA4H (0.57) | LTA4HPARP15PARP10PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1423381-B1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORP (US) | 2007-01-03 | — | — | EP | disclosed |